GlassScriptPhysician profile
Brian Neal Glick
NPI 1790792539
$525.15
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $116 · 2021: $73.82.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $114.83 | 2019-2021 | |
| Novo Nordisk INC | $77.24 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $53.35 | 2019 | |
| Merck Sharp & Dohme LLC | $53.10 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $46.22 | 2019 | |
| Arbor Pharmaceuticals, INC. | $44.09 | 2019-2020 | |
| Esperion Therapeutics, INC. | $32.66 | 2020 | |
| Amarin Pharma, INC. | $32.19 | 2019 | |
| Boston Scientific Corporation | $24.45 | 2021 | |
| Lilly USA, LLC | $18.02 | 2019 | |
| Vanda Pharmaceuticals INC. | $17.79 | 2019 | |
| Medtronic USA, INC. | $11.21 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Glick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.